In an aggressive pancreatic cancer model, 75 percent of mouse tumors vanished completely after treatment with an experimental drug that dismantles the dense fibrosis shielding the cancer cells from the immune system, according to a study published in the journal Cancer Cell.
The research, led by the South Korean biotech company MedPacto, tackles one of the primary obstacles in treating solid tumors. Pancreatic cancer masses typically construct a thick fibrous barrier that physically blocks T cells from penetrating the core of the tumor.
At the same time, the tumor utilizes TGF-beta signaling—a protein pathway that drives fibrosis and suppresses immune function—to reinforce this protective wall. Previous attempts to block TGF-beta directly have failed in clinical trials because the pathway is also essential for normal tissue function, leading to severe adverse events when widely suppressed.
To overcome this toxicity, the research team attached a specialized molecular tag to the experimental drug, designated FEBP-sTβRII. This modification allows the molecule to home in on proteins specific to the tumor microenvironment and accumulate locally, sparing healthy tissue from systemic interference.
When tested across three distinct mouse models of pancreatic cancer, the therapy cleared all tumors in 75 percent of the subjects within the most aggressive model. Among eight treated mice in that group, seven remained alive 270 days following the conclusion of treatment.
Beyond tumor clearance, the study revealed evidence of lasting immune memory. When the researchers reintroduced the same pancreatic cancer cells months later to the mice that had been successfully treated, the animals successfully repelled the renewed cancer cells.
Some of the cured mice even developed cross-protection against bladder and lung cancer cells they had never previously encountered. Transferring T cells from the cured mice into healthy subjects successfully replicated this protective defense against bladder cancer.
Combining the experimental drug with standard PD-1 immunotherapy also cleared tumors in drug-resistant pancreatic cancer models that previously showed zero response to PD-1 treatment alone.
- Mechanism of Action: The experimental compound FEBP-sTβRII targets tumor-specific proteins to neutralize TGF-beta signaling locally, dissolving the dense extracellular matrix without harming healthy organs.
- Immune Infiltration: Removing the fibrous barrier allows cytotoxic T cells to enter the tumor microenvironment and target cancer cells directly.
- Combination Potential: Pairing the drug with checkpoint inhibitors like PD-1 therapies overcomes acquired resistance in hard-to-treat solid tumors.
The research team emphasized that these findings remain restricted to animal preclinical models and have not yet been evaluated in human patients. Human-grade versions of the drug are currently undergoing formal safety evaluations, with a Phase 1 clinical trial scheduled to begin in 2027.
Because FEBP-sTβRII is currently in preclinical development, it is not available for prescription, compassionate use, or clinical administration outside of approved trial protocols. Patients diagnosed with pancreatic ductal adenocarcinoma or other solid tumors should not seek out unregulated TGF-beta inhibitors.
Anyone experiencing persistent abdominal pain, unexplained weight loss, jaundice, or new-onset diabetes should consult an oncologist or gastroenterologist immediately for standard diagnostic imaging and staging.
- Cancer Cell – MedPacto Preclinical Fibrosis and Immunotherapy Study (Cell Press)
